Brentuximab vedotin: clinical updates and practical guidance.

about

Application of Immuno-PET in Antibody-Drug Conjugate Development Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review

P2860

Q58132996-B3AD6911-09AC-4740-9A39-EC9BD8F9ABD0 Q58799247-2CD62B7A-DF81-4D8D-A71D-FB9CE79D5F1E

P2860

Brentuximab vedotin: clinical updates and practical guidance.

Item

http://www.wikidata.org/entity/Q49282959

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Brentuximab vedotin: clinical updates and practical guidance.

@en

Brentuximab vedotin: clinical updates and practical guidance.

@nl

type

Item

label

Brentuximab vedotin: clinical updates and practical guidance.

@en

Brentuximab vedotin: clinical updates and practical guidance.

@nl

prefLabel

Brentuximab vedotin: clinical updates and practical guidance.

@en

Brentuximab vedotin: clinical updates and practical guidance.

@nl

P1476

Brentuximab vedotin: clinical updates and practical guidance.

@en

P2093

Jun Ho Yi

http://www.w3.org/2001/XMLSchema#string

Seok Jin Kim

http://www.w3.org/2001/XMLSchema#string

Won Seog Kim

http://www.w3.org/2001/XMLSchema#string

P2860

The biology and management of systemic anaplastic large cell lymphoma

Lymphomatoid granulomatosis--a single institute experience: pathologic findings and clinical correlations

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.

CD30 in normal and neoplastic cells.

Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

P304

243-253

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5045/BR.2017.52.4.243

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29333400

http://www.w3.org/2001/XMLSchema#string

P932

5762734

http://www.w3.org/2001/XMLSchema#string

Brentuximab vedotin: clinical updates and practical guidance.

about

P2860

P2860

Brentuximab vedotin: clinical updates and practical guidance.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932